{"entity":{"id":"zamra-zambia","kind":"institution","name":"Zambia Medicines Regulatory Authority (ZAMRA)","aka":["ZAMRA","Pharmaceutical Regulatory Authority","PRA Zambia"],"tldr":"Zambia's medicines regulator, set up under the Medicines and Allied Substances Act No. 3 of 2013. It registers medicines, authorises clinical trials and can register a medicine already approved by WHO or a stringent regulator through shorter, reliance-based routes.","summary":"The Zambia Medicines Regulatory Authority, formerly the Pharmaceutical Regulatory Authority, is the statutory medicines regulator established under the Medicines and Allied Substances Act No. 3 of 2013 to regulate the manufacture, importation, storage, distribution, supply, sale and use of medicines and allied substances. Its own history of medicines regulation in Zambia starts with the Pharmacy and Poisons Act of 1941. Its head office is off Kenneth Kaunda International Airport Road in Lusaka, with offices in Chipata and Ndola; the coordinates are approximate.\n\nIts Guidelines for Marketing Authorisation of a Medicine for Human Use (MA/GUD/016, version 1, posted on its site in October 2026) set out abridged routes for medicines already approved elsewhere: the WHO collaborative registration procedure for prequalified products and the WHO procedure for products approved by a stringent regulatory authority, each to be evaluated within 90 days of regulatory time, and a verification route for products approved by a recognised regulatory authority within the previous two years, which requires the unredacted assessment report. Its guideline page publishes documents for the ZAZIBONA collaborative assessment process of southern African regulators. Its clinical trials section reviews and authorises clinical research on regulated products and monitors approved trials.\n\nA 2025 study of the Authority's review practices found that target timelines were not well followed and described ZAMRA as working towards WHO maturity level 3. In October 2026 ZAMRA announced that two of its staff had been appointed to technical committees of the African Medicines Agency.","asOf":"2026-11-11","links":[{"label":"ZAMRA: who we are","url":"https://www.zamra.co.zm/who-we-are/"},{"label":"ZAMRA: guidelines for marketing authorisation of a medicine for human use, MA/GUD/016 (scanned PDF)","url":"https://www.zamra.co.zm/wp-content/uploads/2026/10/MA_GUD_016_Guidelines-for-MA-of-Medcines-for-Human-Use-1.pdf"},{"label":"ZAMRA: guidelines","url":"https://www.zamra.co.zm/guidelines/"},{"label":"ZAMRA: clinical trials","url":"https://www.zamra.co.zm/clinical-trials-regulation/"},{"label":"ZAMRA: statement on appointments to African Medicines Agency technical committees (29 October 2026, PDF)","url":"https://www.zamra.co.zm/wp-content/uploads/2026/10/ZAMRA-AMA-APOINTMENTS-edited.pdf"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["zambia-ministry-of-health","who"],"pathways":[],"terms":[],"trials":[],"people":["makomani-siyanga"],"bottlenecks":[],"keyPapers":["paper-chisha-zamra-good-review-practices-fmed-2025"],"journals":[],"dependsOn":[],"notes":[],"city":"Lusaka","country":"ZM","lat":-15.37,"lng":28.39,"institutionType":"government","website":"https://www.zamra.co.zm","programs":["Marketing authorisation of medicines","Abridged registration through WHO and stringent-regulator procedures","ZAZIBONA collaborative assessment","Clinical trial authorisation","Pharmacovigilance and medical product alerts"]},"route":"/institutions/zamra-zambia/","neighbours":{"institution":[{"id":"zambia-ministry-of-health","kind":"institution","name":"Ministry of Health, Zambia","route":"/institutions/zambia-ministry-of-health/"},{"id":"who","kind":"institution","name":"World Health Organization Cancer Programme","route":"/institutions/who/"}],"person":[{"id":"makomani-siyanga","kind":"person","name":"Makomani Siyanga","route":"/people/makomani-siyanga/"}],"paper":[{"id":"paper-chisha-zamra-good-review-practices-fmed-2025","kind":"paper","name":"Good review practices at ZAMRA, Zambia's medicines regulator","route":"/key-papers/paper-chisha-zamra-good-review-practices-fmed-2025/"}]}}